Hudson Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.27M | Buy |
8,447
+192
| +2% | +$131K | 1.27% | 36 |
|
|
2026
Q1 | $6.38M | Buy |
8,255
+448
| +6% | +$343K | 1.65% | 23 |
|
|
2025
Q4 | $6.03M | Buy |
7,807
+410
| +6% | +$278K | 1.51% | 23 |
|
|
2025
Q3 | $4.16M | Buy |
7,397
+1,292
| +21% | +$731K | 1.1% | 42 |
|
|
2025
Q2 | $3.21M | Buy |
6,105
+647
| +12% | +$361K | 0.91% | 43 |
|
|
2025
Q1 | $3.46M | Buy |
5,458
+497
| +10% | +$342K | 1.06% | 43 |
|
|
2024
Q4 | $3.53M | Buy |
4,961
+357
| +8% | +$300K | 1.1% | 41 |
|
|
2024
Q3 | $4.84M | Sell |
4,604
-125
| -3% | -$139K | 1.54% | 26 |
|
|
2024
Q2 | $4.97M | Buy |
4,729
+88
| +2% | +$85.3K | 1.67% | 21 |
|
|
2024
Q1 | $4.47M | Sell |
4,641
-142
| -3% | -$135K | 1.54% | 27 |
|
|
2023
Q4 | $4.2M | Sell |
4,783
-32
| -0.7% | -$26.4K | 1.52% | 23 |
|
|
2023
Q3 | $3.96M | Buy |
4,815
+323
| +7% | +$254K | 1.58% | 21 |
|
|
2023
Q2 | $3.23M | Buy |
4,492
+74
| +2% | +$57.1K | 1.24% | 38 |
|
|
2023
Q1 | $3.63M | Buy |
4,418
+85
| +2% | +$64.1K | 1.44% | 22 |
|
|
2022
Q4 | $3.13M | Buy |
4,333
+109
| +3% | +$80.4K | 1.24% | 26 |
|
|
2022
Q3 | $2.91M | Buy |
4,224
+226
| +6% | +$142K | 1.45% | 17 |
|
|
2022
Q2 | $2.36M | Buy |
3,998
+221
| +6% | +$144K | 1.12% | 28 |
|
|
2022
Q1 | $2.64M | Buy |
3,777
+144
| +4% | +$91.1K | 1.05% | 23 |
|
|
2021
Q4 | $2.29M | Sell |
3,633
-81
| -2% | -$49.8K | 0.83% | 36 |
|
|
2021
Q3 | $2.25M | Sell |
3,714
-193
| -5% | -$120K | 0.9% | 27 |
|
|
2021
Q2 | $2.18M | Buy |
3,907
+61
| +2% | +$30.9K | 0.9% | 34 |
|
|
2021
Q1 | $1.82M | Buy |
3,846
+130
| +3% | +$63.3K | 0.78% | 39 |
|
|
2020
Q4 | $1.79M | Sell |
3,716
-70
| -2% | -$37.8K | 0.8% | 39 |
|
|
2020
Q3 | $2.12M | Sell |
3,786
-125
| -3% | -$75.8K | 1.04% | 30 |
|
|
2020
Q2 | $2.44M | Sell |
3,911
-1,959
| -33% | -$1.11M | 1.3% | 17 |
|
|
2020
Q1 | $2.87M | Sell |
5,870
-22
| -0.4% | -$9.07K | 1.9% | 13 |
|
|
2019
Q4 | $2.21M | Sell |
5,892
-695
| -11% | -$234K | 1.12% | 28 |
|
|
2019
Q3 | $1.83M | Buy |
6,587
+821
| +14% | +$243K | 1.02% | 32 |
|
|
2019
Q2 | $1.8M | Buy |
5,766
+2,789
| +94% | +$929K | 1.02% | 30 |
|
|
2019
Q1 | $1.22M | Buy |
2,977
+1,061
| +55% | +$437K | 0.74% | 44 |
|
|
2018
Q4 | $716K | Buy |
+1,916
| New | +$701K | 0.52% | 49 |
|
|
2018
Q1 | – | Sell |
-763
| Closed | -$287K | – | 84 |
|
|
2017
Q4 | $287K | Buy |
+763
| New | +$309K | 0.21% | 77 |
|
Other funds holding REGN
Hudson Capital Management's REGN Position: Q2 2026 in Review
Hudson Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q2 2026, buying an estimated $131K and bringing the position to 8,447 shares worth $5.27M. The position accounts for 1.27% of the portfolio, ranked #36.
Hudson Capital Management first reported a position in REGN in Q4 2017 and has held it in 32 quarters since. The position peaked at $6.38M in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Hudson Capital Management held 8,447 shares of Regeneron Pharmaceuticals worth $5.27M as of Q2 2026.
- Hudson Capital Management bought 192 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $131K.
- Regeneron Pharmaceuticals made up 1.27% of Hudson Capital Management's portfolio in Q2 2026, its #36 holding.
- Hudson Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 32 quarters since.
- Hudson Capital Management's Regeneron Pharmaceuticals position peaked at $6.38M in Q1 2026.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Hudson Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.